Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Robert L. Ferris, a head-and-neck surgeon and an expert in cancer immunotherapy was named the executive director of UNC Lineberger Comprehensive Cancer Center and the chief of oncology services at UNC Health.

Cosylab, Mayo Clinic collaborate to advance radiation therapy, support the first carbon ion treatment facility in the U.S.

Cosylab, a provider of control systems and software solutions for complex and precise machines, has entered into a collaboration with Mayo Clinic to advance cancer care in the United States and beyond.

June 14, 2024

Vol.50 No.24

Clinical Roundup

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer.

June 07, 2024

Vol.50 No.23

Clinical Roundup

Cyclophosphamide may expand transplant donor pool for patients with blood cancers

A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to a study conducted by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and colleagues.

May 24, 2024

Vol.50 No.21

Clinical Roundup

Setanaxib combination improves PFS and OS in SCCHN in phase II trial

A phase II trial evaluating setanaxib, Calliditas Therapeutics AB’s lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck shows positive topline results.

May 10, 2024

Vol.50 No.19

Clinical Roundup

Lower MRD prior to HCT associated with better outcomes in FLT3-ITD AML

Patients in remission after being treated for a high-risk blood cancer are likely to have better outcomes if no trace of the cancer is detectable before the patients receive donor blood cells.

May 03, 2024

Vol.50 No.18

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

YOU MAY BE INTERESTED IN

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Cosylab, Mayo Clinic collaborate to advance radiation therapy, support the first carbon ion treatment facility in the U.S.

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

Cyclophosphamide may expand transplant donor pool for patients with blood cancers

Setanaxib combination improves PFS and OS in SCCHN in phase II trial

Lower MRD prior to HCT associated with better outcomes in FLT3-ITD AML

Renew today!

Subscriber content

Login